Novo-Ipramide · DIN 02210479 · 250 mcg/mL · Inh Sol-20mL Pk
Limited Use, Reason for Use code 256, 257, 258, 259 required; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.Discontinued October 26, 2015 · checked November 19, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below); Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Novo-Ipramide · DIN 02210479
Manufacturer: Novopharm Ltd.; listing date 1999-04-15
Health Canada: Cancelled post market since 2015-10-26 · brand NOVO-IPRAMIDE - LIQ 0.25MG/ML · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE .25 MG/ML · company Novopharm limited · schedule Prescription
Novo-Ipramide: Formulary list price $6.31 per unit (the source does not state the unit; exact figure $6.3140). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02210479)
Source record
DIN 02210479: Novo-Ipramide
Raw flags: sec12=Y, sec3=Y
Item: 120800039; group id 205; item number 0374; lccId 00030; manufacturer id NOP
Source form: Inh Sol-20mL Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $6.3140; ministry $6.3140
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02210479
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20153
Interchangeable products
AA-Ipravent · DIN 02126222 · $6.3140
Atrovent · DIN 00731439 · not recorded
PMS-Ipratropium · DIN 02231136 · $6.3140
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since October 26, 2015 — choose a marketed DIN from the same-category list.